45.85
price down icon1.25%   -0.58
after-market Dopo l'orario di chiusura: 45.85
loading
Precedente Chiudi:
$46.43
Aprire:
$46.51
Volume 24 ore:
296.92K
Relative Volume:
0.34
Capitalizzazione di mercato:
$2.99B
Reddito:
$58.89M
Utile/perdita netta:
$-240.88M
Rapporto P/E:
-14.79
EPS:
-3.1
Flusso di cassa netto:
$-239.96M
1 W Prestazione:
-1.08%
1M Prestazione:
-2.74%
6M Prestazione:
+3.36%
1 anno Prestazione:
+6.93%
Intervallo 1D:
Value
$45.52
$46.88
Intervallo di 1 settimana:
Value
$44.11
$47.30
Portata 52W:
Value
$19.45
$53.27

Kymera Therapeutics Inc Stock (KYMR) Company Profile

Name
Nome
Kymera Therapeutics Inc
Name
Telefono
857-285-5314
Name
Indirizzo
500 NORTH BEACON STREET, 4TH FLOOR, WATERTOWN
Name
Dipendente
208
Name
Cinguettio
Name
Prossima data di guadagno
2025-02-21
Name
Ultimi documenti SEC
Name
KYMR's Discussions on Twitter

Confronta KYMR con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Biotechnology icon
KYMR
Kymera Therapeutics Inc
45.85 3.26B 58.89M -240.88M -239.96M -3.10
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
472.27 120.73B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
564.64 61.80B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
328.00 42.46B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
591.74 35.22B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
296.46 31.99B 3.81B -644.79M -669.77M -6.24

Kymera Therapeutics Inc Stock (KYMR) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2025-07-03 Ripresa Morgan Stanley Overweight
2025-06-03 Aggiornamento B. Riley Securities Neutral → Buy
2025-06-03 Aggiornamento Morgan Stanley Equal-Weight → Overweight
2025-06-02 Aggiornamento BofA Securities Neutral → Buy
2025-05-20 Ripresa Stifel Buy
2025-03-13 Iniziato Citigroup Buy
2024-12-10 Iniziato BTIG Research Buy
2024-12-06 Iniziato BMO Capital Markets Market Perform
2024-12-02 Aggiornamento Wells Fargo Equal Weight → Overweight
2024-11-18 Iniziato Stephens Overweight
2024-09-09 Ripresa Leerink Partners Outperform
2024-08-26 Aggiornamento Wolfe Research Peer Perform → Outperform
2024-04-22 Iniziato Oppenheimer Outperform
2024-02-15 Iniziato Wolfe Research Peer Perform
2024-01-04 Aggiornamento JP Morgan Neutral → Overweight
2024-01-03 Downgrade BofA Securities Buy → Neutral
2023-12-19 Downgrade Wells Fargo Overweight → Equal Weight
2023-06-30 Iniziato Truist Buy
2023-05-05 Aggiornamento Raymond James Mkt Perform → Outperform
2022-12-06 Downgrade Credit Suisse Outperform → Neutral
2022-11-08 Iniziato Raymond James Mkt Perform
2022-08-15 Iniziato Jefferies Buy
2022-08-03 Iniziato Goldman Buy
2022-07-20 Iniziato SVB Leerink Mkt Perform
2022-04-28 Iniziato Credit Suisse Outperform
2022-03-10 Iniziato JP Morgan Neutral
2022-02-10 Iniziato Wells Fargo Overweight
2021-09-30 Iniziato B. Riley Securities Neutral
2021-09-30 Iniziato Stifel Buy
2021-09-10 Downgrade BofA Securities Buy → Neutral
2021-05-21 Iniziato UBS Buy
2021-04-14 Iniziato Berenberg Buy
2020-12-04 Iniziato H.C. Wainwright Buy
2020-09-15 Iniziato BofA Securities Neutral
2020-09-15 Iniziato Cowen Outperform
2020-09-15 Iniziato Guggenheim Buy
2020-09-15 Iniziato Morgan Stanley Equal-Weight
Mostra tutto

Kymera Therapeutics Inc Borsa (KYMR) Ultime notizie

pulisher
Jul 24, 2025

Will Kymera Therapeutics Inc. stock benefit from AI tech trendsOutstanding trading profits - jammulinksnews.com

Jul 24, 2025
pulisher
Jul 23, 2025

What drives Kymera Therapeutics Inc. stock priceDouble-digit growth - Autocar Professional

Jul 23, 2025
pulisher
Jul 23, 2025

Is Kymera Therapeutics Inc. a good long term investmentFree Stock Market Query - Autocar Professional

Jul 23, 2025
pulisher
Jul 22, 2025

What analysts say about Kymera Therapeutics Inc. stockHigh-profit stock alerts - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 22, 2025

Kymera Therapeutics Inc. Stock Analysis and ForecastExplosive capital appreciation - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 18, 2025

What makes Kymera Therapeutics Inc. stock price move sharplyAlpha Stock Ideas - beatles.ru

Jul 18, 2025
pulisher
Jul 18, 2025

Kymera Surges 70% in 3 Months: Buy, Sell or Hold the Stock? - Yahoo Finance

Jul 18, 2025
pulisher
Jul 17, 2025

Goldman Sachs Initiates Coverage on Kymera Therapeutics as Early-Stage Biotech with Potential Upside of 33.75% - AInvest

Jul 17, 2025
pulisher
Jul 15, 2025

How Kymera Therapeutics Inc. stock performs during market volatilityFree Risk Assessment Services - Newser

Jul 15, 2025
pulisher
Jul 10, 2025

Forecasting the Future: Targeted Protein Degradation - openPR.com

Jul 10, 2025
pulisher
Jul 10, 2025

Morgan Stanley Assumes Coverage of Kymera Therapeutics (KYMR) Stock with Overweight Rating - Insider Monkey

Jul 10, 2025
pulisher
Jul 08, 2025

Kymera Therapeutics shares fall 1.26% intraday amid Gilead Sciences' clinical hold on HIV treatment trials. - AInvest

Jul 08, 2025
pulisher
Jul 07, 2025

Kymera Therapeutics stock price target lowered to $65 at Brookline Capital - Investing.com Canada

Jul 07, 2025
pulisher
Jul 06, 2025

(KYMR) Investment Analysis - news.stocktradersdaily.com

Jul 06, 2025
pulisher
Jul 03, 2025

Gilead Sciences Signs $750M Deal For Cancer Drug With Kymera Therapeutics, Predicts Hit To Its Annual Profit - MSN

Jul 03, 2025
pulisher
Jul 03, 2025

Kymera Therapeutics Q4 2024 slides: immunology pipeline advances with $600M cash infusion - Investing.com Canada

Jul 03, 2025
pulisher
Jul 02, 2025

Kymera Therapeutics (KYMR) director group buys $13.9 million in stock By Investing.com - Investing.com South Africa

Jul 02, 2025
pulisher
Jun 30, 2025

Kymera Therapeutics: Baker Bros acquire $28.8m in shares By Investing.com - Investing.com South Africa

Jun 30, 2025
pulisher
Jun 30, 2025

Kymera Therapeutics: Baker Bros acquire $28.8m in shares - Investing.com

Jun 30, 2025
pulisher
Jun 30, 2025

Gilead, Kymera Partner in $750M Deal to Develop Novel Molecular Glue Degraders for Cancer - MSN

Jun 30, 2025
pulisher
Jun 27, 2025

Oppenheimer Adjusts Price Target for Kymera Therapeutics (KYMR) | KYMR Stock News - GuruFocus

Jun 27, 2025
pulisher
Jun 27, 2025

Oppenheimer Adjusts Price Target for Kymera Therapeutics (KYMR) - GuruFocus

Jun 27, 2025
pulisher
Jun 27, 2025

KYMR: Key Insights on Recent Developments | KYMR Stock News - GuruFocus

Jun 27, 2025
pulisher
Jun 27, 2025

Nuclear stocks, Kymera Therapeutics, Estee Lauder - TradingView

Jun 27, 2025
pulisher
Jun 27, 2025

Gilead and Kymera in pact to develop cancer drugs - MSN

Jun 27, 2025
pulisher
Jun 26, 2025

Kymera Therapeutics (KYMR) Target Price Lowered by Wells Fargo | KYMR Stock News - GuruFocus

Jun 26, 2025
pulisher
Jun 26, 2025

KYMR Collaborates With GILD; Stock Down on Sanofi Deal Update - TradingView

Jun 26, 2025
pulisher
Jun 25, 2025

Kymera Therapeutics launches $250 million public stock offering - Investing.com

Jun 25, 2025
pulisher
Jun 25, 2025

Gilead signs up to $750 million cancer drug deal with Kymera Therapeutics - PharmaLive

Jun 25, 2025
pulisher
Jun 25, 2025

Gilead (GILD) Enters Agreement with Kymera to Enhance Cancer Tre - GuruFocus

Jun 25, 2025
pulisher
Jun 25, 2025

Kymera Therapeutics (KYMR) Advances IRAK4 Partnership with Sanofi | KYMR Stock News - GuruFocus

Jun 25, 2025
pulisher
Jun 25, 2025

Gilead and Kymera in pact to develop cancer drugs (GILD) (KYMR) - Seeking Alpha

Jun 25, 2025
pulisher
Jun 24, 2025

Gilead (GILD) Enters Agreement with Kymera for Novel Cancer Trea - GuruFocus

Jun 24, 2025
pulisher
Jun 15, 2025

When (KYMR) Moves Investors should Listen - news.stocktradersdaily.com

Jun 15, 2025

Kymera Therapeutics Inc Azioni (KYMR) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
$23.63
price up icon 3.32%
$36.59
price up icon 1.61%
$103.52
price up icon 0.08%
$27.57
price down icon 1.57%
$114.57
price down icon 0.03%
biotechnology ONC
$296.46
price up icon 0.55%
Capitalizzazione:     |  Volume (24 ore):